Artelo Biosciences reports preclinical ART26.12 data
Artelo Biosciences (NASDAQ:ARTL) reported new preclinical data for ART26.12, a selective FABP5 inhibitor currently in Phase 1 development, in a mouse model of spinal cord injury–related neuropathic pain.










